AtriCure Reports First Quarter 2023 Financial Results

 A leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2023 financial results.

“We had an extraordinary start to 2023 driven by strength across our platforms globally. We are experiencing robust demand from physicians to treat patients and remain excited for the extensive opportunities in our markets,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “As we look forward, we are focused on growing our patient impact, expanding clinical science and innovation, and increasing leverage across our operations.”

First Quarter 2023 Financial Results

Revenue for the first quarter 2023 was $93.5 million, an increase of 25.4% (an increase of 25.9% on a constant currency basis) over first quarter 2022 revenue. U.S. revenue was $78.2 million, an increase of $15.9 million or 25.6%, compared to first quarter 2022. U.S. revenue growth was driven by sales in all key product lines, highlighted by EnCompass® clamp in open ablation, cryoSPHERE® probe for post-operative pain management and AtriClip® Flex·V® in the appendage management franchise. International revenue increased $3.0 million or 24.4% (an increase of 27.7% on a constant currency basis) to $15.3 million, across all franchises and geographic regions. On a sequential basis, worldwide revenue for the first quarter 2023 increased approximately 6.2% from fourth quarter 2022.

Gross profit for the first quarter 2023 was $69.6 million compared to $55.6 million for the first quarter 2022. Gross margin was 74.5% for both the first quarters 2023 and 2022, with the current quarter reflecting leverage of our operations and production efficiencies, offset by continuing supply chain cost increases and shift in product mix. Loss from operations for the first quarter 2023 was $5.8 million, compared to $14.2 million for the first quarter 2022, reflecting strong revenue growth, improving leverage of our operating costs and a gain from legal settlement. Basic and diluted net loss per share was $0.14 for the first quarter 2023, compared to $0.33 for the first quarter 2022.

Adjusted EBITDA was positive for the first quarter 2023 at $1.9 million, compared to negative $4.2 million for first quarter of 2022. Adjusted loss per share for the first quarter 2023 was $0.23, compared to $0.33 for the first quarter 2022.

Constant currency revenue, adjusted EBITDA and adjusted loss per share are non-GAAP measures. We discuss these non-GAAP measures and provide reconciliations to GAAP measures later in this release.

2023 Financial Guidance

Full year 2023 revenue is projected to be $385 million to $392 million, reflecting growth of approximately 17% to 19% over full year 2022. Management now expects full year 2023 positive adjusted EBITDA of approximately $2 million, and full year 2023 adjusted loss per share of approximately $1.10 to $1.15.

Conference Call

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, May 2, 2023 to discuss its first quarter 2023 financial results. To access the webcast, please visit the Investors page of AtriCure’s corporate website at Participants are encouraged to register more than 15 minutes before the webcast start time. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on Twitter @AtriCure.

Forward-Looking Statements

This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. This press release also includes forward-looking projected financial information that is based on current estimates and forecasts. Actual results could differ materially. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visit as well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. Except where otherwise noted, the information contained in this release is as of May 2, 2023. We assume no obligation to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.

Use of Non-GAAP Financial Measures

To supplement AtriCure’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, AtriCure provides certain non-GAAP financial measures in this release as supplemental financial metrics.

Revenue reported on a constant currency basis is a non-GAAP measure, calculated by applying previous period foreign currency exchange rates to each of the comparable periods. Management analyzes revenue on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on revenue, the Company believes that evaluating growth in revenue on a constant currency basis provides an additional and meaningful assessment of revenue to both management and investors.

Adjusted EBITDA is calculated as net loss before other income/expense (including interest), income tax expense, depreciation and amortization expense, share-based compensation expense, acquisition costs, legal settlement, impairment of intangible asset and change in fair value of contingent consideration liabilities. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. The excluded items vary in frequency and/or impact on our continuing results of operations and management believes that the excluded items are typically not reflective of our ongoing core business operations and financial condition. Further, management uses adjusted EBITDA for both strategic and annual operating planning. A reconciliation of adjusted EBITDA reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Income (Loss) (Adjusted EBITDA)” later in this release.

Adjusted loss per share is a non-GAAP measure which calculates the net loss per share before non-cash adjustments in fair value of contingent consideration liabilities, impairment of intangible asset and legal settlement. A reconciliation of adjusted loss income per share reported in this release to the most comparable GAAP measure for the respective periods appears in the table captioned “Reconciliation of Non-GAAP Adjusted Loss Per Share” later in this release.

The non-GAAP financial measures used by AtriCure may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for AtriCure’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financials measures included in this press release, and not to rely on any single financial measure to evaluate our business.

 Three Months Ended
March 31,
 2023   2022 
United States Revenue:   
Open ablation$25,142  $18,974 
Minimally invasive ablation 9,637   8,615 
Pain management 11,068   8,014 
Total ablation 45,847   35,603 
Appendage management 32,342   26,669 
Total United States 78,189   62,272 
International Revenue:   
Open ablation 7,286   6,492 
Minimally invasive ablation 1,867   1,533 
Pain management 228   140 
Total ablation 9,381   8,165 
Appendage management 5,924   4,139 
Total International 15,305   12,304 
Total revenue 93,494   74,576 
Cost of revenue 23,885   18,981 
Gross profit 69,609   55,595 
Operating expenses:   
Research and development expenses 15,327   13,629 
Selling, general and administrative expenses 60,064   56,116 
Total operating expenses 75,391   69,745 
Loss from operations (5,782)  (14,150)
Other expense, net (616)  (977)
Loss before income tax expense (6,398)  (15,127)
Income tax expense 78   56 
Net loss$(6,476) $(15,183)
Basic and diluted net loss per share$(0.14) $(0.33)
Weighted average shares used in computing net loss per share:   
Basic and diluted 46,107   45,528 
 March 31,
 December 31,
Current assets:   
Cash, cash equivalents, and short-term investments$135,860  $121,113 
Accounts receivable, net 45,661   42,693 
Inventories 48,848   45,931 
Prepaid and other current assets 7,956   5,477 
Total current assets 238,325   215,214 
Long-term investments 25,561   51,509 
Property and equipment, net 39,607   38,833 
Operating lease right-of-use assets 4,605   3,787 
Goodwill and intangible assets, net 273,382   274,120 
Other noncurrent assets 1,620   1,985 
Total assets$583,100  $585,448 
Liabilities and Stockholders’ Equity   
Current liabilities:   
Accounts payable and accrued liabilities$51,794  $52,920 
Current maturities of debt and leases 10,677   5,472 
Total current liabilities 62,471   58,392 
Long-term debt 51,940   56,834 
Finance lease liabilities 8,883   9,147 
Operating lease liabilities 3,725   3,095 
Other noncurrent liabilities 1,236   1,226 
Total liabilities 128,255   128,694 
Stockholders’ equity:   
Common stock 47   47 
Additional paid-in capital 790,965   787,422 
Accumulated other comprehensive loss (3,072)  (4,096)
Accumulated deficit (333,095)  (326,619)
Total stockholders’ equity 454,845   456,754 
Total liabilities and stockholders’ equity$583,100  $585,448 
Reconciliation of Non-GAAP Adjusted Income (Loss) (Adjusted EBITDA) 
 Three Months Ended
March 31,
 2023   2022 
Net loss, as reported$(6,476) $(15,183)
Income tax expense 78   56 
Other expense, net 616   977 
Depreciation and amortization expense 2,943   2,867 
Share-based compensation expense 8,760   7,049 
Gain from legal settlement (4,000)   
Non-GAAP adjusted income (loss) (adjusted EBITDA)$1,921  $(4,234)
 Reconciliation of Non-GAAP Adjusted Loss Per Share 
 Three Months Ended
March 31,
  2023   2022 
Net loss, as reported$(6,476) $(15,183)
Gain from legal settlement (4,000)   
Non-GAAP adjusted net loss$(10,476) $(15,183)
Basic and diluted adjusted net loss per share$(0.23) $(0.33)
Weighted average shares used in computing adjusted net loss per share   
Basic and diluted 46,107   45,528 


Newsletter Updates

Enter your email address below and subscribe to our newsletter